Immutep's Efti Trials Show Mixed Results as TACTI-004 Futility Analysis Continues
Event summary
- Pooled analysis of five efti trials showed a 7.7-month median overall survival benefit in biological responders across four tumor types.
- IMP761 met primary safety endpoint and demonstrated significant pharmacodynamic activity in first-in-human results.
- TACTI-004 Phase III trial discontinued due to futility, with root cause analysis expected in Q3 CY26.
- Company has A$68.87 million in cash reserves as of June 30, 2026, with cost-reduction measures extending runway into H1 CY28.
The big picture
Immutep's mixed clinical results highlight the high-risk, high-reward nature of biotech development. While efti shows promise in immune activation across multiple tumor types, the TACTI-004 setback underscores the challenges of Phase III trials. The company's financial position remains strong, but strategic pivots may be necessary to maintain momentum in both oncology and autoimmune indications.
What we're watching
- Clinical Validation
- Whether the pooled analysis results for efti can offset the setback from TACTI-004 and restore investor confidence.
- Autoimmune Pipeline
- The pace at which IMP761 advances in autoimmune disease trials following positive Phase I data.
- Financial Runway
- How effectively cost-reduction measures preserve capital amid reduced trial activity and potential revenue impacts.
Related topics